Loading
A phase 1/2 trial of Asciminib, Dexamethasone, Vincristine, Blinatumomab, Methotrexate and Cytarabine in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, now recruiting.
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) is a phase 1/2 interventional study registered as NCT07387926 by Novartis Pharmaceuticals, with 50 participants planned, started 2026-07-05 and due to reach its primary completion in 2033-09-19. Interventions recorded: Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone, Vincristine, Blinatumomab and Methotrexate (intrathecal).
Shares Asciminib, Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag pipeline.
Shares Asciminib, Advanced Accelerator Applications (Novartis), Novartis, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Cytarabine, Methotrexate, Dexamethasone and the tag pipeline.
Shares Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL), Cytarabine, Methotrexate, Dexamethasone and the tag pipeline.